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Abstract
BACKGROUND: Obesity is an expanded health problem worldwide and it is blamed for a startling rise in type 1 
diabetes (T1DM), the interaction between obesity, autoimmune processes, and glucose homeostasis is a growing 
field of study.
AIM: This study was undertaken to predict the role of the inflammatory cytokines (interleukin [IL]-17 and IL-10) as 
biomarkers in early screening for obesity and T1DM and to determine the relation of inflammatory cytokines with 
diabetic complications especially nephropathy.
SUBJECTS AND METHODS: The target group consisted of 92 children with type 1 diabetes children who were 
diagnosed according to the criteria provided by American Diabetes Association Diabetic; cases were divided into 
two groups, Group 1 (overweight and obese diabetics) and Group 2 (normal weight diabetic children). The levels 
of serum IL-17 and IL-10 were assayed in these children by an enzyme-linked immunosorbent assay. Serum 
triglycerides (TG) and cholesterol levels were measured as well as urinary microalbumin level was estimated for 
detection of nephropathy.
RESULTS: Diabetic overweight and obese children exhibited significantly 3.8 folds more at risk to be bad glycemic 
control than diabetic children with normal body mass index (BMI). Furthermore, overweight and obese diabetic 
children displayed significantly 15 times more at risk of having nephropathy than diabetic children with normal BMI. 
Low serum level of IL 10 and high level of IL 17 showed a significant association with high BMI in diabetic children. 
High HBA1c, low IL 10, and long disease duration were significantly considered as predominant risk factors for 
diabetic nephropathy in diabetic children.
CONCLUSION: The obtained data from these investigations proved that overweight and obese children have a low 
serum level of IL-10 and high serum IL-17 levels. The relationship between IL-10/IL-17 can be applied as a good 
marker for the inflammatory state and these inflammatory interleukins can be employed as biomarkers in early 
screening for obesity and T1DM. Furthermore, these interleukins can be utilized as a predictor for early diabetic 
complications, particularly nephropathy.
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Introduction
Overweight and obesity in children are growing 
global health issues. Obesity is defined as an excessive 
accumulation of fat that occurred due to entertaining a 
lot of calories than the body can consume. They have 
emerged as one of the major global health problems. 
In fact, previous studies have estimated that more than 
2 billion adults worldwide are overweight (body mass 
index [BMI] ≥25 kg/m2), and 671 million of them are 
clinically obese (BMI ≥30 kg/m²) [1]. Accordingly, it was 
suggested that more than 51% of the population all 
over the world will be obese by 2030 [2].
Excessive weight gain leads to severe 
complications such as hypertension, diabetes, 
atherosclerosis, and hyperlipidemia, which have been 
defined as “metabolic syndrome.” However, only half of 
the obese patients with BMI from 30 to 50 kg/m2 had 
metabolic disorders [3].
Type 1 diabetes mellitus (T1DM) is an 
autoimmune disease characterized as multifactorial 
disorders attributable to T cell-mediated destruction of 
the pancreatic β cells caused by the interaction between 
inherited and ecological factors [4]. It accounts for 
80–90% in diabetic children and adolescents [5] and 
its incidence was 387 million in 2014, and a raise of 
approximately 205 million new cases are expected to 
occur by 2035 [6]. Some of the diabetic patients are 
asymptomatic, particularly in children with absolute 
insulin insufficiency who may undergo polyphagia, 
polydipsia, polyuria, blurred vision, and weight loss. 
Uncontrolled diabetic individuals may cause stupor, 
coma, and ketoacidosis or nonketotic hyperosmolar 
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syndrome that may lead to death [7], DM1 is strongly 
related to chronic low-grade inflammation, which is 
largely presented in obese individuals, it is related 
to the fact that, in obese individuals, visceral white 
adipose tissue (AT) is characterized by hyperplasic and 
hypertrophic adipocytes, with infiltration of inflammatory 
macrophages, endothelial cells activation, and fibrosis. 
Another important factor is the phenomena called 
inflammaging, which consists of the positive regulation 
of the chronic low-grade inflammatory. Thus, high levels 
of pro-inflammatory cytokines like IL-17 combined with 
the reduction of anti-inflammatory cytokines, like IL-10, 
lead to an imbalance in the inflammatory composition 
of the innate and acquired immune system and have 
been related to the development and maintenance of 
several chronic diseases like T1DM [8].
Diabetic nephropathy occurs in 30% of people 
with T1DM, mostly in post adolescents. Albumin 
excretion rate increases until frank albuminuria occur 
which may result in renal failure [9].
Cytokines are extracellular proteins of low 
molecular weight that acts as immune response 
mediators. They perform in highly complex pathways 
that regulate the inflammatory process, and they are 
essential to conduct response to the lesion site. Obesity 
is associated with low-grade chronic inflammation. 
Indeed, AT in obese individuals are the former site of 
progressive infiltration by pro-inflammatory immune 
cells, which, together with increased inflammatory 
adipokine secretion, induce adipocyte insulin resistance. 
IL-17 and IL10 cells are part of obese AT infiltrating cells 
and are likely to be promoted by adipose [3].
Low-grade chronic inflammation and stimulation 
of the innate immune system are identified to be strongly 
linked to the pathogenesis of DM [10]. Pro- and anti-
inflammatory cytokines have been suggested to be 
implicated in the events of diabetes [11]. Previous reports 
revealed that definite pro- and/or anti-inflammatory 
cytokines are able to interfere with insulin-responsive 
glucose uptake and stimulate insulin resistance [12]. 
IL-10 and IL-17 have been found to be connected with 
the pathophysiology of DM1; however, their interplay in 
the modulation of diabetogenic T-cells remains unknown.
IL-10 plays a central role in regulating immune 
response and limiting inflammation. IL-10 suppresses 
inflammation through various mechanisms, including 
inhibition of the synthesis of pro-inflammatory cytokines 
such as IL12 and TNFα through suppression of p65 
NF-kB and c-Rel activity in macrophages [13]. IL-10 is 
also important in the downregulation of the release of 
reactive oxygen species and nitrogen intermediates, 
regulation of antigen presentation capacity and immune 
tolerance [14], and suppression of proliferative and 
cytotoxic T cell responses [15].
IL-17 was discovered as cytotoxic T-lymphocyte 
associated antigen 8 in 1993 [16].
After 10 years, it was identified that the cellular 
source of this cytokine is Th17 cells [17].
Th17 cells are likely to play a major role in the 
propagation of inflammation and in the immunometabolism, 
which can be easily modified with a hypercaloric diet as it 
was mentioned before that the hypercaloric diet induces 
enrichment of pathogenic Th17 cells, in several metabolic 
organs [18]. However, data obtained from human T1DM 
studies and mouse models suggest the involvement of 
Th17 in the pathogenesis of this disease [19].
This study was intended to explore the 
mechanism behind the role of IL-10 and IL-17 in 
inflammation associated with obesity in diabetic children. 
Furthermore, the study was extended to find out the 
possibility of utilizing these cytokines as early predictors 
for T1DM complications, particularly nephropathy.
Subjects and Methods
Between October 2019 and March 2020, 92 
diabetic children (T1DM) attending the Unit for Pediatric 
Diabetes and Endocrinology, Children Hospital, Ain 
Shams University, were selected for this study. The 
study group of T1DM children was diagnosed according 
to the criteria provided by the American Diabetes 
Association. The parents gave informed consent and 
children of 10 years of age or older signed their informed 
consent by themselves after full explanation of the aim 
of the work, plan of action and blood as well as urine 
sampling, the protocol of the study was approved by the 
Ethics Committees for Medical Research of the National 
Research Centre, Egypt. The diabetic children age 
ranged between 5 and 15 years were divided into two 
groups: 34 overweight and obese diabetics (Group 1) 
and nonobese diabetics (Group 2). All anthropometric 
parameters have been obtained using standardized 
equipment and following the recommendations of the 
International Biological Program [20]. Obesity was 
considered when BMI exceeded 95th percentile while 
overweight was considered when BMI was from 85th to 95th 
percentile and other normal weight diabetic children [21]. 
Assessment of BMI was done using categories reported 
by the World Health Organization (WHO) Child Growth 
Charts Standards for age and sex [22].
Participants were excluded for any of the 
following reasons: The presence of other chronic or 
inflammatory disease, drugs or medications (other than 
insulin), presence of known renal disease or systemic 
disease, or acute infection at the time of testing.
Laboratory and clinical data
The background information of subjects such 
as age, gender, weight, height, daily dose of insulin 
injection, disease duration, and family history of diabetes 
was recorded. Furthermore, detailed medical history 
and physical examination were carried out. Disease 
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duration was defined in this study as the day of the initial 
diagnosis of diabetes to the day of blood collection.
Samples collection for biochemical analysis
From each child, 5 ml of fasting blood samples 
were withdrawn; 4 ml were collected in a vacuum tube 
free from EDTA for separation of serum, and 1 ml was put 
in another tube with anticoagulant for determination of 
glycated hemoglobin. Serum samples were separated 
using a cooling centrifuge (4°C) at 1800× g for 10 
min and stored at −20°C until analysis. Triglycerides 
and cholesterol were quantified using colorimetric 
techniques on Synchron Cx7 (Beckman Instruments 
Inc., Brea, California, USA) [23]. Glycated hemoglobin 
was measured in whole blood colorimetrically using a 
kit obtained from Biosystems (Spain) according to the 
method of Roberts et al. [24].
According to the manufacturer’s protocol, 
IL-10 and IL-17 were assayed by employing the Human 
cytokine ELISA set. IL-10 ELISA kit was purchased 
from SinoGeneClon Biotech Co., Ltd., China, for the 
quantitative determination of Human IL-10 concentrations, 
Catalog No: SG-10271. IL-17 ELISA kit was purchased 
from SinoGeneClon Biotech Co., Ltd., China, for the 
quantitative determination of Human IL-17 concentrations, 
Catalog No: SG-10278. For random urinary microalbumin 
measurement, an early morning midstream urine 
specimens were used. The cloudy samples were 
centrifuged before use and the clear supernatants 
were stored at −20°C until analysis. Microalbumin 
concentrations were estimated in urine using a Minineph 
Microalbumin kit based on the nephelometry method on 
a Minineph nephelometer (AD200) (Birmingham, UK). 
The diagnosis of nephropathy was established when 
microalbumin in the urine was more than 30 µgldl [25].
Statistical analysis
Data entry was carried on Excel sheet and 
statistical analysis was done using the SPSS software 
program, version 18.0 (SPSS Inc., PASW Statistics for 
Windows, Version 18.0. Chicago, USA). Chi-square 
was done for qualitative data that were presented 
by numbers and percentages. t-test was done for 
comparison between two means. A simple linear 
correlation (Pearson’s correlation) for quantitative data 
was also done. P value was considered statistically 
significant when p < 0.05 and considered statistically 
highly significant when its value was <0.01.
Results
A total number of 92 Egyptian diabetic 
children were included in this study. The study group 
was divided into two groups: Group 1 (38 overweight 
and obese diabetic) and Group 2 (52 normal weight 
diabetic cases). Diabetic cases were further classified 
according to their glycated hemoglobin (HbA1c) level 
into Group A (67 controlled HbA1c <8%) and Group 
B (25 uncontrolled HbA1c >8%) diabetic groups. All 
children were age- and sex-matched.
The mean age was 9.58 ± 2.585 years old in 
overweight and obese diabetes versus 9.56 ± 2.377 
years old in normal-weight diabetes with no significant 
difference between them (p > 0.05), as shown in 
Table 1. The data presented in Table 1 also shows a 
statistically significant difference between obese and 
normal-weight diabetic children regarding cholesterol, 
IL10, IL17, HBA1c, and insulin dose. Meanwhile, 
there is no significant difference between both groups 
regarding age, disease duration, or triglyceride level 
(p > 0.05).
Table 1: Comparison between both diabetic groups regarding 
some clinical and biochemical findings according to BMI
Items Group 1 Group 2 t-test p
Mean ± SD
Age (years) 9.58 ± 2.585 9.56 ± 2.377 0.045 0.964
Disease duration (years) 6.50 ± 1.484 6.37 ± 1.218 0.459 0.647
Cholesterol (mg/dL) 181.63 ± 22.114 152.57 ± 15.162 7.482 0.000*
Triglycerides (mg/dL) 76.63 ± 11.034 72.67 ± 11.384 1.666 0.099
IL10 (pg/ml) 3.608 ± 0.9763 7.959 ± 0.9591 −21.269 0.000*
IL17 (pg/ml) 196.947 ± 21.5825 141.930 ± 13.8687 14.884 0.000*
HBA1c (g%) 10.182 ± 2.1145 8.156 ± 1.5811 5.259 0.000*
Insulin dose (unit/kg/day) 1.382 ± 0.3083 1.104 ± 0.1843 5.400 0.000*
Group 1 (Overweight and obese) *p<0.05 is significant, Group 2 (Normal BMI). BMI: Body mass index, 
HBA1c: Glycated hemoglobin, IL: Interleukin.
The data depicted in Table 2 shows a 
statistically significant difference between diabetic 
children with good and bad glycemic control regarding 
BMI percentile, cholesterol, IL10, and insulin dose 
(p < 0.05) but there is no significant difference between 
both groups regarding age, disease duration, TG, or 
IL17 (p > 0.05).
Table 2: Comparison between the diabetic groups regarding 
some clinical and biochemical findings according to the 
glycemic control
Items Group 1 Group 2 t-test p
Mean ± SD
Age (years) 9.20 ± 1.756 9.70 ± 2.663 −0.872 0.386
Disease duration (years) 6.20 ± 1.323 6.51 ± 1.330 −0.988 0.326
BMI centile 56.72 ± 19.974 74.10 ± 22.329 −3.414 0.001*
Cholesterol (mg/dL) 155.80 ± 18.690 167.85 ± 24.021 −2.263 0.026*
Triglycerides (mg/dL) 75.84 ± 13.576 73.73 ± 10.459 0.791 0.431
IL10 (pg/ml) 7.256 ± 1.8301 5.754 ± 2.4148 2.819 0.006*
IL17 (pg/ml) 155.504 ± 27.9879 168.069 ± 33.3187 −1.676 0.097
Insulin dose (unit/kg/day) 1.048 ± 0.1295 1.282 ± 0.2923 −3.855 0.000*
Group A (controlled HbA1c <8%), Group B (uncontrolled HbA1c >8%), *p<0.05 is significant. BMI: Body 
mass index, HBA1c: Glycated hemoglobin, IL: Interleukin.
Table 3 shows that diabetic overweight and 
obese children displayed significantly 3.8 folds more at 
risk to be bad glycemic control than diabetic children 
with normal BMI (Table 3).
Table 3: Association between glycemic control and obesity
Items Glycemic control Total
Group A (controlled 
HbA1c <8%)
Group B (uncontrolled 
HbA1c >8%)
Obesity
Overweight and obese
Count 33 5 38
% within obesity 86.8 13.2 100.0
Normal BMI
Count 34 20 54
% within obesity 63.0 37.0 100.0
Odds ratio=3.882, 95% CI 1.304–11.556, p=0.015*, *p<0.05 is significant. BMI: Body mass index, HBA1c: 
Glycated hemoglobin, CI: Confidence interval.
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Figure 1: Correlation between body mass index and interleukin-10
Discussion
Long-term complications of DM1 are secondary 
to the damaging impacts of the metabolic consequences 
of insulin deficiency on tissues of different body organs. 
Maintaining good control of diabetes by preventing 
prolonged hyperglycemia is essential to avoid developing 
complications it in later life [9].
Figure 2: Correlation between body mass index and interleukin-17
Obesity is well known to predispose individuals 
to metabolic syndrome (MetS). The mechanisms involved 
in obesity-related pathological processes involve various 
immune cells, which release IL10 and IL17 [18].
Table 7: Multiple logistic regression analysis of risk factors of 
diabetic nephropathy
Items B Adjusted OR 95% CI for OR Sig.
Lower Upper
HBA1c 1.161 3.192 1.193 8.543 0.021*
BMI centile −0.084 0.919 0.813 1.039 0.177
IL10 −1.710 0.181 0.034 0.955 0.044*
IL17 0.020 1.020 0.960 1.084 0.521
Cholesterol −0.030 0.971 0.906 1.039 0.393
Disduration 1.377 3.963 1.089 14.418 0.037*
Age 0.427 1.533 0.900 2.612 0.116
Insulin dose −1.188 0.305 0.004 25.414 0.599
Triglycerides 0.042 1.043 0.943 1.154 0.409
Constant −12.218 0.000 0.344
*p < 0.05 is significant. BMI: Body mass index, HBA1c: Glycated hemoglobin, IL: Interleukin, OR: Odds 
ratio, CI: Confidence interval.
The data in Table 4 show that overweight 
and obese diabetic children displayed significantly 15 
times more at risk of having nephropathy than diabetic 
children with normal BMI (Table 4).
Table 4: Association between obesity and diabetic nephropathy
Items Nephropathy Total
Yes No
BMI
Overweight and obese
Count 14 24 38
% within obesity 36.8 63.2 100.0
Normal BMI
Count 2 52 54
% within obesity 3.7 96.3 100.0
Odds ratio=15.167, 95%, CI 3.192–72.070, p=0.001*, *p<0.05 is significant. BMI: Body mass index,  
HBA1c: Glycated hemoglobin, CI: Confidence interval.
The data presented in Table 5 showed a 
statistically significant negative correlation between 
IL10 and IL17, BMI, cholesterol, HBA1c, and insulin 
dose, while there is a significant positive correlation 
between IL17 and BMI, cholesterol, and HBA1c.
Table 5: Correlation between different variables in diabetic 
children
Items IL10 (pg/ml) IL17 (pg/ml)
Age (years)
r −0.036 −0.060
p 0.736 0.567
Disease duration (years)
r −0.085 −0.073
p 0.421 0.491
BMI centile
r −0.837** 0.742**
p 0.000 0.000
Cholesterol (mg/dL)
r −0.667** 0.493**
p 0.000 0.000
Triglycerides (mg/dL)
r −0.188 0.033
p 0.072 0.755
IL10 (pg/ml)
r 1 −0.732**
p 0.000
IL17 (pg/ml)
r −0.732** 1
p 0.000
HBA1c (g%)
r −0.500** 0.400**
p 0.000 0.000
Insulin dose (unit/kg/day)
r −0.527** 0.393**
p 0.000 0.000
**Correlation is significant at the 0.01 level (2-tailed). *Correlation is significant at the 0.05 level (2-tailed). 
BMI: Body mass index, HBA1c: Glycated hemoglobin, IL: Interleukin.
Table 6 and Figures 1 and 2 showed that low 
level of IL 10 and high level of IL 17 were significantly 
associated with high BMI in diabetic children.
Table 6: Multiple linear regression analysis of factors affecting 
BMI in diabetic children
Items Unstandardized 
coefficients
Standardized 
coefficients
t Sig.
B SE Beta
(Constant) 20.213 24.367 0.830 0.409
HBA1c (g%) 1.382 0.761 0.125 1.816 0.073
IL10 (pg/ml) −4.655 0.971 −0.478 −4.795 0.000*
IL17 (pg/ml) 0.206 0.056 0.289 3.666 0.000*
Cholesterol (mg/dL) 0.113 0.071 0.115 1.598 0.114
Triglycerides (mg/dL) 0.198 0.111 0.098 1.779 0.079
Insulin dose (unit/kg/day) −1.488 5.770 −0.018 −0.258 0.797
*p<0.05 is significant. HBA1c: Glycated hemoglobin, IL: Interleukin.
Table 7 showed that high HBA1c, low IL 10, 
and long disease duration are all considered as risk 
factors of diabetic nephropathy in diabetic children.
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There is growing evidence linking IL10 and IL17 to obesity 
[26]. metabolic syndrome (MetS) and cardiovascular 
disease are also linked to IL10 and IL17 [27].
This research provides relevant information on 
the influence of body composition on inflammatory and 
biochemical markers in overweight and obese diabetic 
and normal weight diabetic children. We demonstrate 
how body composition interferes with the balance of 
cytokines, especially IL-10 and IL-17, and how it may 
exert an effect on the biochemical parameters and risk 
factors associated with T1DM.
The purpose of this study was to predict if the 
inflammatory cytokines (IL-17 and IL-10) were beneficial 
as biomarkers in early screening for obesity and T1DM 
and to determine the relation of inflammatory cytokines 
with diabetic complications, especially nephropathy.
Comparison of different variables in both 
obese and normal-weight groups according to BMI 
group revealed that serum cholesterol, IL-10, IL-17, 
HBA1c levels, and insulin dose are the factors showing 
a significant difference between both groups. And 
to some extent, the findings of previous researches 
came in accordance with our conclusion as the study 
done by Israel et al. [8]. We next performed multiple 
linear regression analysis to predict variants that are 
independently associated with BMI and we found that 
IL-10 and IL-17 concentration are strongly associated 
with BMI. This study showed that IL-10 concentration 
is negatively correlated with blood cholesterol but 
not triglycerides. Moreover, this comes in agreement 
with a study done by Jung and Choi, who stated that 
IL-10 exerts essential control over the biochemical 
parameters such as LDL, VLDL, HDL, triglycerides, and 
glucose [28]. While on the contrast of our findings Jung 
and Choi reported that such a correlation pattern is not 
detected in overweight women, in whom IL-10 showed a 
negative correlation only with total cholesterol and LDL.
In the current study, the overweight and obese 
diabetic children had a low level of IL-10 and this agrees 
with a study done by Jung et al. [29], in which when 
compared overweight and obese with their normal-
weight counterparts, overweight and obese children 
had lower serum IL-10. In contrast, a study done by 
Pereira et al. revealed that obese women have higher 
serum concentrations of IL-10 as feedback generated 
from the elevated expression of pro-inflammatory 
cytokines as a result of obesity [30]. However, that 
increase is not sufficient to govern the development of 
the pro-inflammatory profile [31].
Many other studies investigating IL10 in 
children and young adolescents with obesity have 
yielded conflicting results [32], [33], [34], [35]. Another 
study, included 80 obese and 80 nonobese Egyptian 
children, agreed with our results as these authors stated 
that serum levels of IL-10 are significantly lower in the 
former group [32]. This could be explained by a study 
done by Lauridsen et al., gave accentual evidence 
concerning this as they demonstrated that in the 
prefrontal cortex of neurologically and psychiatrically 
healthy humans, a gradual increase in BMI is associated 
with discrete signs of altered gene expression, that 
leads to downregulation of mRNA expression of the 
anti-inflammatory cytokine IL-10 [33].
However, this comes in conflict with 
Calcaterra et al. in a study, including 70 severely 
obese and 30 normal-weight children aged 11.46±3.42 
years old, Calcaterra et al. stated that serum IL-10 
concentrations are higher in severely obese children 
compared to normal weight [34]. Tam et al. recorded 
no differences in IL-10 concentration between normal 
and overweight children at 8 years old; however, at 15 
years old, serum IL-10 is elevated in overweight and 
obese girls when compared to normal weight girls of 
the same age [35].
The study done by Chang et al. suggested 
that the effect of obesity on IL-10 serum concentration 
varies with age, but in this current study, we did not find 
a correlation between IL-10 and IL-17 and age neither 
in the obese group nor in the normal-weight group [29].
In the present study, IL17 is significantly 
increased in overweight and obese diabetic compared 
to normal weight diabetic and this agrees with a study 
of Sumarac-Dumanovic who observed significant 
enhancement in circulating IL-17 and IL-23 cytokines 
in obese as compared with lean individuals [36]. The 
relationship between obesity and serum level of IL-17 
has been further demonstrated in a sheep model, 
where maternal obesity provoked an inflammatory 
state in the fetal intestine, with increased levels 
of inflammatory cytokines, particularly IL-17 [37]. 
Infiltrating IL-17+-secreting cells have also been 
noticed more abundant, in obese versus lean AT, and 
in visceral versus subcutaneous AT [38]. Dalmas et al. 
have shown that single populations of IL-17+ IL-22− 
and IL-17−IL-22+ and double populations of IL-17+ 
IL-22+ CD4+ T cells are highly induced in the mucosal 
tissues of obese subjects, as compared with non-obese 
[39]. Supporting the implication of IL-17 in the MetS, 
the levels of IL-17 expression in liver or muscle were 
shown to correlate with insulin resistance [38], and the 
blockade of IL-17 resulted in the decrease of hepatic 
inflammation in the non-alcoholic steatohepatitis 
syndrome (NASH) [40].
This current study also demonstrated that pro-
inflammatory cytokine IL-17 and the anti-inflammatory 
IL-10 are significantly negatively correlated and this 
matches the findings of Winer et al. which showed that 
in obese rats the increase of IL-6 due to obesity causes 
maturation of Th17 and secretion of IL-17which inhibits 
IL-10 secretion and Treg development and this, in turn, 
intensified inflammation in the body [41].
Comparing the two groups of diabetics 
according to their glycemic control level using HbA1c 
8% as a cutoff (controlled [<8%] and uncontrolled [>8%] 
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diabetic group), a significant difference between good 
and bad glycemic control has been found regarding 
BMI, IL10, cholesterol and insulin dose. Diabetic 
overweight and obese children were significantly 3.8 
folds more at risk to be bad glycemic control than 
diabetic children with normal BMI. This result comes 
in line with that of El-Wakeel et al.’s study [42]; this 
strong association was confirmed by many other 
studies [8], [18].
The current study showed that overweight 
and obese diabetic children are significantly at higher 
risk of having nephropathy than diabetic children with 
normal BMI. This coincides with the study done by Zu 
et al. which explained this as obesity is associated 
with hyperleptinemia, which contributes to a decline in 
eGFR and pathological processes [43]. Changwei et 
al. did not agree with this result in their study, where 
481 patients with nephropathy were finally enrolled 
in the study. There was no significant difference in 
clinical and pathological characteristics among the 
four-group patients categorized by BMI. After matching 
with propensity scores, no significant correlation 
between BMI and renal outcomes was seen [44]. 
These findings spotlight the effect of impaired control 
of hyperglycemia and BMI on the risk of premature 
development of complications in the pediatric diabetic 
population. There are several limitations in our study; 
the cross-sectional nature of the current study and the 
relative small sample size are the common limitations 
of the study. However, in the light of data documented 
by the results of the present study, we put forward the 
evidence that high serum IL17 and lower IL10 levels in 
type 1 diabetic children together with obesity might be 
collateral to deterioration in diabetic cases and more 
emerging of diabetic complications as nephropathy.
Conclusion
This study proved that overweight and obesity 
in children T1DM are associated with low serum IL-10 
concentration and high serum IL-17. The changes in 
these interleukins in overweight and obese diabetic 
children may further implicate to the inflammatory 
environment associated with obesity. The relationship 
between IL-10/IL-17 can be applied as a good marker 
for the inflammatory state, and we encourage further 
studies with a large sample size to confirm this 
hypothesis. This study is considered as innovative 
and relevant research in children population showing 
that serum IL-10 and IL-17 levels can be served 
as predictors of obesity and diabetes-associated 
complications.
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